



ASX Announcement

For immediate release

16 July 2020

CSL Appoints New Non-Executive-Director

CSL Limited (ASX:CSL; USOTC:CSLLY) is pleased to announce the appointment of Mr Pascal Soriot as an independent Non-Executive Director, to be effective from 19 August 2020.

CSL's Chairman, Dr Brian McNamee AO said "Pascal is a highly experienced international business leader who brings to CSL's Board a lifelong passion for science and medicine and international pharmaceutical industry insight. His deep experience in both established and emerging markets complements CSL's global footprint and the values he has displayed in leading AstraZeneca will support CSL's values and purpose to deliver for patients."

Mr Soriot has served as the Chief Executive Officer of AstraZeneca, a global biopharmaceutical company since 2012 where he has led a strong pipeline of new products and delivered high growth in total shareholder returns.

From 2010-2012, he served as Chief Operating Officer of Roche's pharmaceuticals division. Prior to that Mr Soriot was Chief Executive Officer of Genentech, a biologics business, where he led its successful integration with Roche.

Mr Soriot has worked in a variety of senior pharmaceutical management roles in France, Switzerland, Japan, Australia and the United States.

Mr Soriot is a doctor of veterinary medicine and holds an MBA from the French Business School, HEC. He resides in the United Kingdom and holds dual French and Australian citizenship.

Approved for Release
Fiona Mead
Company Secretary

For further information, please contact:

Media:

Jemimah Brennan
Head of Asia Pacific Communications
Telephone: +61 412 635 483
Email: Jemimah.Brennan@csl.com.au

Investors:

Mark Dehring
Head of Investor Relations
Telephone: +61 3 9389 3407
Email: mark.dehring@csl.com.au